BioSpace News Archive

BioGenes today announces the establishment of a Scientific Advisory Board which includes the four renowned experts.

In addition, the Company announced the appointment of Elyse Seltzer, M.D., as UroGen’s Senior Vice President of Clinical Development.

The data obtained from the initial 18-week period which assess a high dose of the active vaccine administered for the first time show no safety concerns and allow continuation of the recruitment.

PharmaMar presented new preclinical data on plitidepsin showing how it regulates the viability and function of bone cells in combination with other anti-multiple myeloma drugs.

Aldevron and DNA Technologies. Inc. announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFi Cas9 Nuclease—which is patented by IDT.

The publication by Lu et al, “BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency”, demonstrates that both BET inhibitors can reactivate HIV-1 from latency.

FDA also granted OMIDRIA an additional six months of U.S. market exclusivity.

Janssen R&D today announced data from the Phase 3 ALCYONE study, showing that DARZALEX in combination with bortezomib, melphalan and prednisone significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.

DNAnexus announced the availability of the DeepVariant bioinformatics tool on the DNAnexus Platform.